VERAXA Biotech to Showcase BiTAC at Industry Conferences

ZURICH, SWITZERLAND, May 29, 2025 – VERAXA Biotech AG (VERAXA), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), announced today it will be attending the upcoming ASCO Annual Meeting and BIO International Convention.

At the conferences, Christoph Antz, CEO, and additional members of the VERAXA leadership team will be meeting with potential partners and investors, showcasing the Company’s novel Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform, and sharing the Company’s growth plans as it prepares to list on the NASDAQ later this year. VERAXA is leveraging its proprietary BiTAC platform to develop highly specific dual-target oncology therapies with less off-tumor toxicity and enhanced tumor specificity. The Company is currently pursuing nine discovery and development programs comprised of next-generation bispecific antibody-drug conjugates (ADCs) and T-cell engagers (TCEs).

... Read on — Members only